title: Clinical outcome, proteome kinetics and angiogenic factors in serum after thermoablation of colorectal liver metastases.
abstract: BACKGROUND
  Thermoablation is used to treat patients with unresectable colorectal liver metastases (CRLM). We analyze clinical outcome, proteome kinetics and angiogenic markers in patients treated by cryosurgical ablation (CSA) or radiofrequency ablation (RFA).
  
  
  METHODS
  205 patients underwent CSA (n = 20), RFA (n = 22), partial hepatectomy (PH, n = 134) or were found truly unresectable (n = 29). Clinical outcome, proteome transitions and angiogenic response in serum were analyzed at various time points after ablation.
  
  
  RESULTS
  Median overall survival in CSA patients (17.6 months) was worse (p < 0.0001) when compared to RFA treated patients (51.7 months) and patients after PH (43.4 months). The complication rate was higher in the CSA group (50%) as compared to the RFA group (22%). Proteomics analyses showed consistently more changes in serum protein abundance with CSA compared to RFA. In the first four days after ablation a pro-angiogenic serum response occurred.
  
  
  CONCLUSIONS
  RFA of CRLM is superior to CSA with a median survival which equals survival in patients after PH. Proteomics analyses suggests a more aggravated serum response to CSA compared to RFA. Thermoablation is associated with changes in serum levels of angiogenic factors favouring a pro-angiogenic environment, but without differences between RFA and CSA.
authors.forename: Marieke W J L A E
authors.initials: MW
authors.lastname: Wertenbroek
authors.forename: Marianne
authors.initials: M
authors.lastname: Schepers
authors.forename: Hannetta J
authors.initials: HJ
authors.lastname: Kamminga-Rasker
authors.forename: Jan T
authors.initials: JT
authors.lastname: Bottema
authors.forename: Anneke C
authors.initials: AC
authors.lastname: Muller Kobold
authors.forename: Han
authors.initials: H
authors.lastname: Roelofsen
authors.forename: Koert P
authors.initials: KP
authors.lastname: de Jong
mesh_terms: D000368:Aged; D043925:Angiogenesis Inducing Agents / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood; D017115:Catheter Ablation; D015179:Colorectal Neoplasms / Q000097:blood* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood* / Q000401:mortality / Q000556:secondary / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis; D020543:Proteome / Q000032:analysis*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D015996:Survival Rate
chemical_list: D043925:Angiogenesis Inducing Agents; D014408:Biomarkers, Tumor; D020543:Proteome